105 related articles for article (PubMed ID: 24065329)
21. Atazanavir for the treatment of human immunodeficiency virus infection.
Busti AJ; Hall RG; Margolis DM
Pharmacotherapy; 2004 Dec; 24(12):1732-47. PubMed ID: 15585441
[TBL] [Abstract][Full Text] [Related]
22. Treatment of HIV infection with once-daily regimens.
Permpalung N; Putcharoen O; Avihingsanon A; Ruxrungtham K
Expert Opin Pharmacother; 2012 Nov; 13(16):2301-17. PubMed ID: 23043453
[TBL] [Abstract][Full Text] [Related]
23. Effectiveness and safety of generic fixed-dose combination of tenofovir/emtricitabine/efavirenz in HIV-1-infected patients in Western India.
Pujari S; Dravid A; Gupte N; Joshi K; Bele V
Medscape J Med; 2008; 10(8):196. PubMed ID: 18924648
[TBL] [Abstract][Full Text] [Related]
24. Once-daily single-tablet regimens: a long and winding road to excellence in antiretroviral treatment.
Llibre JM; Clotet B
AIDS Rev; 2012; 14(3):168-78. PubMed ID: 22833060
[TBL] [Abstract][Full Text] [Related]
25. Persistent decline in estimated but not measured glomerular filtration rate on tenofovir may reflect tubular rather than glomerular toxicity.
Vrouenraets SM; Fux CA; Wit FW; Garcia EF; Furrer H; Brinkman K; Hoek FJ; Abeling NG; Krediet RT; Reiss P;
AIDS; 2011 Nov; 25(17):2149-55. PubMed ID: 21857491
[TBL] [Abstract][Full Text] [Related]
26. Tolerance and viral resistance after single-dose nevirapine with tenofovir and emtricitabine to prevent vertical transmission of HIV-1.
; Arrivé E; Chaix ML; Nerrienet E; Blanche S; Rouzioux C; Coffie PA; Kruy Leang S; McIntyre J; Avit D; Srey VH; Gray G; N'Dri-Yoman T; Diallo A; Ekouévi DK; Dabis F
AIDS; 2009 Apr; 23(7):825-33. PubMed ID: 19307941
[TBL] [Abstract][Full Text] [Related]
27. Raltegravir: new Drug. Alternative to enfuvirtide/darunavir in multidrug-resistant HIV.
Prescrire Int; 2008 Aug; 17(96):135-7. PubMed ID: 19480091
[TBL] [Abstract][Full Text] [Related]
28. Simplification therapy with once-daily emtricitabine, didanosine, and efavirenz in HIV-1-infected adults with viral suppression receiving a protease inhibitor-based regimen: a randomized trial.
Molina JM; Journot V; Morand-Joubert L; Yéni P; Rozenbaum W; Rancinan C; Fournier S; Morlat P; Palmer P; Dupont B; Goujard C; Dellamonica P; Collin F; Poizot-Martin I; Chene G;
J Infect Dis; 2005 Mar; 191(6):830-9. PubMed ID: 15717256
[TBL] [Abstract][Full Text] [Related]
29. Tenofovir: quo vadis anno 2012 (where is it going in the year 2012)?
De Clercq E
Med Res Rev; 2012 Jul; 32(4):765-85. PubMed ID: 22581627
[TBL] [Abstract][Full Text] [Related]
30. Once-daily nevirapine XR: a brief overview of the safety and efficacy of a new formulation.
Bhatti L; Gladstein J
J Int Assoc Physicians AIDS Care (Chic); 2012; 11(6):369-73. PubMed ID: 22930796
[TBL] [Abstract][Full Text] [Related]
31. Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment.
Smith KY; Patel P; Fine D; Bellos N; Sloan L; Lackey P; Kumar PN; Sutherland-Phillips DH; Vavro C; Yau L; Wannamaker P; Shaefer MS;
AIDS; 2009 Jul; 23(12):1547-56. PubMed ID: 19542866
[TBL] [Abstract][Full Text] [Related]
32. Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-Lamivudine: a randomized, 96-week trial.
Martin A; Bloch M; Amin J; Baker D; Cooper DA; Emery S; Carr A
Clin Infect Dis; 2009 Nov; 49(10):1591-601. PubMed ID: 19842973
[TBL] [Abstract][Full Text] [Related]
33. Incidence of HIV-1 drug resistance among antiretroviral treatment-naive individuals starting modern therapy combinations.
von Wyl V; Yerly S; Böni J; Shah C; Cellerai C; Klimkait T; Battegay M; Bernasconi E; Cavassini M; Furrer H; Hirschel B; Vernazza PL; Ledergerber B; Günthard HF;
Clin Infect Dis; 2012 Jan; 54(1):131-40. PubMed ID: 22057700
[TBL] [Abstract][Full Text] [Related]
34. Etravirine, a next-generation nonnucleoside reverse-transcriptase inhibitor.
Johnson LB; Saravolatz LD
Clin Infect Dis; 2009 Apr; 48(8):1123-8. PubMed ID: 19275497
[TBL] [Abstract][Full Text] [Related]
35. Daily dosing of highly active antiretroviral therapy.
Rosenbach KA; Allison R; Nadler JP
Clin Infect Dis; 2002 Mar; 34(5):686-92. PubMed ID: 11823957
[TBL] [Abstract][Full Text] [Related]
36. Emerging patterns and implications of HIV-1 integrase inhibitor resistance.
Geretti AM; Armenia D; Ceccherini-Silberstein F
Curr Opin Infect Dis; 2012 Dec; 25(6):677-86. PubMed ID: 23086187
[TBL] [Abstract][Full Text] [Related]
37. Emerging antiretroviral drugs.
Fernández-Montero JV; Vispo E; Soriano V
Expert Opin Pharmacother; 2014 Feb; 15(2):211-9. PubMed ID: 24289800
[TBL] [Abstract][Full Text] [Related]
38. Emtricitabine/tenofovir in the treatment of HIV infection: current PK/PD evaluation.
Uglietti A; Zanaboni D; Gnarini M; Maserati R
Expert Opin Drug Metab Toxicol; 2012 Oct; 8(10):1305-14. PubMed ID: 22943210
[TBL] [Abstract][Full Text] [Related]
39. Role of raltegravir in HIV-1 management.
Rokas KE; Bookstaver PB; Shamroe CL; Sutton SS; Millisor VE; Bryant JE; Weissman SB
Ann Pharmacother; 2012 Apr; 46(4):578-89. PubMed ID: 22496475
[TBL] [Abstract][Full Text] [Related]
40. Dysphagia in a HIV patient: concern for the etiology?
Bobba RK; El-Dika SS; Arsura EL
South Med J; 2007 Jan; 100(1):61-2. PubMed ID: 17269528
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
